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Hypertension is the most common modifiable risk factor 
for cardiovascular events and mortality in the world (1). 
The 2017 American College of Cardiology/American 
Heart Association hypertension guidelines published 
online on November 13, 2017 stated that a normal blood 
pressure is less than 120/80 mmHg (2). Elevated blood 
pressure is 120–129/<80 mmHg. Stage 1 hypertension is 
a systolic blood pressure of 130–139 mmHg or a diastolic 
blood pressure of 80–89 mmHg. Stage 2 hypertension 
is a systolic blood pressure of 140 mmHg and higher or 
a diastolic blood pressure of 90 mmHg and higher (2). 
Automated validated devices should be used for measuring 
blood pressure. According to the 2017 American College 
of Cardiology/American Heart Association guidelines, the 
overall prevalence of hypertension in United States adults is 
49% in non-Hispanic white men and 47% in non-Hispanic 
white women, 59% in non-Hispanic African-American men 
and 60% in non-Hispanic African-American women, and 
46% in Hispanic men and 41% in Hispanic women (2).
The 2017 American College of Cardiology/American 
Heart Association hypertension guidelines stated that the 
absolute cardiovascular risk reduction from lowering of blood 
pressure is greater at higher absolute levels of cardiovascular 
disease risk (2). These new guidelines recommend that drug 
therapy of hypertension should be guided by predicted 
cardiovascular disease risk in conjunction with blood 
pressure (2-5). Persons who have hypertension and a 10-
year atherosclerotic cardiovascular risk less than 15% with 
a systolic blood pressure of 120–159 mmHg and a coronary 
artery calcium score greater than 100 also have an increased 
risk for cardiovascular events and should be considered for 
intensive lowering of blood pressure (6).
Lifestyle measures should be used for treating a systolic 
blood pressure between 120–129 mmHg with a diastolic blood 
pressure less than 80 mmHg (2,7). Adults with an untreated 
systolic blood pressure of 131–159 mmHg or diastolic blood 
pressure of 81–99 mmHg should be screened for white coat 
hypertension by either home blood pressure monitoring or by 
daytime ambulatory blood pressure monitoring (2,8).
The 2017 American College of Cardiology/American 
Heart Association hypertension guidelines recommended 
antihypertensive treatment using lifestyle measures plus 
blood pressure lowering drugs for secondary prevention of 
recurrent cardiovascular disease events in persons with clinical 
cardiovascular disease (coronary heart disease, congestive heart 
failure, and stroke) in adults who have an average systolic blood 
pressure of 130 mmHg and higher or an average diastolic 
blood pressure of 80 mmHg and higher (2,9-11). These new 
hypertension guidelines recommended antihypertensive 
therapy using lifestyle measures plus blood pressure lowering 
drugs for primary prevention of cardiovascular disease in 
adults who have an estimated 10-year risk of atherosclerotic 
cardiovascular disease greater than or equal to 10% using a 
risk calculator (12) with an average systolic blood pressure of 
130 mmHg and higher or an average diastolic blood pressure 
of 80 mmHg and higher (2,13-16).
The 2017 American College of Cardiology/American 
Heart Association hypertension guidelines also recommended 
antihypertensive therapy using lifestyle measures plus 
blood pressure lowering drugs for primary prevention of 
cardiovascular disease in adults who have an estimated 10-
year risk of atherosclerotic cardiovascular disease of less 
than 10% using a risk calculator (12) with an average systolic 
blood pressure of 140 mmHg and higher or an average 
diastolic blood pressure of 90 mmHg and higher (2,13,14). 
These recent guidelines also recommended initiating 
antihypertensive drug therapy with two first-line drugs 
from different classes either as separate agents or in a fixed-
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dose combination in adults who have a blood pressure of 
140/90 mmHg and higher or who have a blood pressure more 
than 20/10 mmHg above their blood pressure target (2,17). 
White coat hypertension needs to be excluded before starting 
antihypertensive drug therapy in adults with hypertension at 
low risk for atherosclerotic cardiovascular disease (2). 
The target blood pressure goal in adults with hypertension 
treated with antihypertensive drugs should be less than 
130/80 mmHg (2). A subsequent editorial will discuss which 
antihypertensive drugs to use for treating different clinical 
conditions and the target blood pressure goal for treating 
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